Bio-Rad Laboratories, Inc. BIO.B
365.08
0.00
0.00%
as of 24 Sep
- Market cap
- $10.3B
- P/E
- 43.8×
Follow BIO.B
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 11.12 | 45.54 | 35.59 |
P/S ratio |
3.00 | 3.28 | 2.90 | 3.06 | |
P/FCF ratio |
22.63 | 22.49 | 20.87 | 22.33 | |
P/Operating CF |
63.44 | 51.37 | 69.39 | 80.34 | |
P/B ratio |
1.14 | 1.14 | 1.09 | 1.11 | |
Price to Tangible BV |
1.33 | 1.26 | 1.23 | 1.23 | |
EV/Sales |
2.91 | 3.15 | 2.76 | 2.90 | |
EV/EBITDA |
33.20 | 172.31 | 123.95 | 141.53 | |
EV/Operating CF |
15.17 | 15.28 | 13.99 | 15.26 | |
EV/FCF |
21.99 | 21.59 | 19.87 | 21.16 | |
Quick Ratio |
3.61 | 3.87 | 2.17 | 2.14 | |
Current Ratio |
5.44 | 5.62 | 3.21 | 3.14 | |
Net Debt/EBITDA |
(3.31) | 2.84 | (10.60) | (5.71) | |
Debt/Assets |
12.40% | 11.37% | 12.29% | 11.74% | |
Debt/Equity |
0.18 | 0.16 | 0.18 | 0.17 | |
Asset Turnover |
0.25 | 0.26 | 0.27 | 0.25 | |
Operating CF/Net income |
(0.35) | 0.23 | (0.21) | 0.27 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.92% | 0.00% | 0.00% | 9.40% | |
Selling, General and Administrative Expense of Revenue |
31.67% | 31.88% | 35.87% | 32.57% | |
Intangible Assets out of Total Assets |
0.10 | 0.07 | 0.08 | 0.07 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.02) | (0.03) | 0.00 | (0.01) | |
Graham Number |
0.00 | 414.65 | 186.92 | 224.21 | |
Earnings Yield |
(8.53%) | 9.00% | 2.20% | 2.81% | |
Free Cash Flow Yield |
4.42% | 4.45% | 4.79% | 4.48% | |
Revenue per Share |
24.25 | 25.43 | 21.96 | 24.34 | |
Operating CF per Share |
4.49 | 6.05 | 4.01 | 3.69 | |
Capex per Share |
(1.18) | (1.68) | (1.11) | (1.20) | |
Free Cash Flow per Share |
3.31 | 4.37 | 2.90 | 2.49 | |
Cash per Share |
52.69 | 56.51 | 58.04 | 60.51 | |
Shareholders Equity per Share |
250.22 | 273.40 | 254.15 | 268.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
250.22 | 273.40 | 254.15 | 268.22 | |
Free Cash Flow |
89.20 | 119.10 | 78.20 | 66.60 | |
Working Capital |
2,319.70 | 2,389.20 | 2,025.10 | 2,059.20 | |
Capital Expenditures |
(31.70) | (45.80) | (29.90) | (32.10) | |
Net Current Asset Value |
(117.60) | (216.70) | 3.40 | (57.60) | |
EV/EBIT |
33.20 | 172.31 | 123.95 | 141.53 | |
Capex to Sales |
0.05 | 0.07 | 0.05 | 0.05 | |
Net Profit Margin |
(52.36%) | 103.87% | (89.02%) | 57.05% | |
Price to Operating Income |
34.16 | 179.46 | 130.23 | 149.34 | |
| Other line items | |||||
Average Receivables |
463.32 | 456.55 | 425.45 | 455.85 | |
Average Payables |
125.49 | 125.65 | 135.50 | 141.40 | |
Average Inventory |
793.74 | 750.35 | 780.30 | 789.70 | |
Average Assets |
10,149.94 | 9,970.30 | 9,658.45 | 10,233.05 | |
Average Common Equity |
7,112.33 | 7,011.45 | 6,765.35 | 7,151.30 |
Columns are period end dates